Mucosal p-STAT1/3 correlates with histologic disease activity in Crohn’s disease and is responsive to filgotinib

References

• Vermeire S, Schreiber S, Petryka R, Keuhbacker T, Hebuterne X, Roblin X, and Klopocka M, et al. Clinical remission in patients with moderate-to-severe Crohn’s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet. 2017;389(10066):179–191. doi:10.1016/S0140-6736(16)32537-5.
   Web of Science ®Google Scholar
• Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG clinical guideline: Management of Crohn’s disease in adults. Am J Gastroenterol. 2018;113(4):481–517. doi:10.1038/ajg.2018.27.
   PubMed Web of Science ®Google Scholar
• White JR, Jairath V, Moran GW. Evolution of treatment targets in Crohn’s disease. Best Pract Res Clin Gastroenterol. 2019;38–39:101599. doi:10.1016/j.bpg.2019.02.001.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, D’Haens G, Dotan I, Dubinsky M, Feagan B, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): Determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110(9):1324–1338. doi:10.1038/ajg.2015.233.
   PubMed Web of Science ®Google Scholar
• Tajra JB, Calegaro JU, de Paula AP, Bachour D, Silveira D, Lozi M, Cavalcanti H. Correlation and concordance measures between clinical, endoscopic and histological scores activity in Crohn’s disease under treatment. Scand J Gastroenterol. 2019;54(4):441–445. doi:10.1080/00365521.2019.1596305.
   PubMed Web of Science ®Google Scholar
• Brennan GT, Melton SD, Spechler SJ, Feagins LA. Clinical implications of histologic abnormalities in ileocolonic biopsies of patients with Crohn’s Disease in remission. J Clin Gastroenterol. 2017;51(1):43–48. doi:10.1097/MCG.0000000000000507.
   PubMed Web of Science ®Google Scholar
• Park S, Abdi T, Gentry M, Laine L. Histological disease activity as a predictor of clinical relapse among patients with ulcerative colitis: Systematic review and meta-analysis. Am J Gastroenterol. 2016;111(12):1692–1701. doi:10.1038/ajg.2016.418.
   PubMed Web of Science ®Google Scholar
• Calafat M, Lobaton T, Hernandez-Gallego A, Mañosa M, Torres P, Cañete F, Cabré E, Ojanguren I, Domènech E. Acute histological inflammatory activity is associated with clinical relapse in patients with ulcerative colitis in clinical and endoscopic remission. Dig Liver Dis. 2017;49(12):1327–1331. doi:10.1016/j.dld.2017.08.041.
   PubMedGoogle Scholar
• Ponte A, Pinho R, Fernandes S, Rodrigues A, Alberto L, Silva JC, Silva J, Rodrigues J, Sousa M, Silva AP, et al. Impact of histological and endoscopic remissions on clinical recurrence and recurrence-free time in ulcerative colitis. Inflamm Bowel Dis. 2017;23(12):2238–2244. doi:10.1097/MIB.0000000000001275.
   PubMed Web of Science ®Google Scholar
• Li K, Friedman JR, Chan D, Pollack P, Yang F, Jacobstein D, Brodmerkel C, Gasink C, and Feagan BG, et al. Effects of ustekinumab on histologic disease activity in patients with Crohn’s disease. Gastroenterology. 2019;157(4):1019–1031 e7. doi:10.1053/j.gastro.2019.06.037.
   PubMed Web of Science ®Google Scholar
• Lowenberg M, Vermeire S, Mostafavi N, Hoentjen F, Franchimont D, Bossuyt P, Hindryckx P, Rispens T, and de Vries A, et al. Vedolizumab induces endoscopic and histologic remission in patients with Crohn’s disease. Gastroenterology. 2019;157(4):997–1006 e6. doi:10.1053/j.gastro.2019.05.067.
   PubMed Web of Science ®Google Scholar
• Danese S, Sandborn WJ, Colombel JF, Vermeire S, Glover SC, Rimola J, Siegelman J, Jones S, and Bornstein JD, et al. Endoscopic, radiologic, and histologic healing with vedolizumab in patients with active Crohn’s disease. Gastroenterology. 2019;157(4):1007–1018 e7. doi:10.1053/j.gastro.2019.06.038.
   PubMed Web of Science ®Google Scholar
• Gong W, Guo K, Zheng T, Fang M, Xie H, Li W, Hong Z, Ren H, and Gu G, et al. Correlation between endoscopic and histological validated scoring indices in Crohn’s disease. Dig Liver Dis. 2019;51(6):812–817. doi:10.1016/j.dld.2019.01.010.
   PubMedGoogle Scholar
• Christensen B, Erlich J, Gibson PR, Turner JR, Hart J, Rubin DT. Histologic healing is more strongly associated with clinical outcomes in ileal Crohn’s disease than endoscopic healing. Clin Gastroenterol Hepatol. 2019. doi:10.1016/j.cgh.2019.11.056.
   Web of Science ®Google Scholar
• Van Rompaey L, Galien R, van der Aar EM, Clement-Lacroix P, Nelles L, Smets B, Lepescheux L, Christophe T, and Conrath K, et al. Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases. J Immunol. 2013;191(7):3568–3577. doi:10.4049/jimmunol.1201348.
   PubMed Web of Science ®Google Scholar
• Villarino AV, Kanno Y, O’Shea JJ. Mechanisms and consequences of JAK-STAT signaling in the immune system. Nat Immunol. 2017;18(4):374–384. doi:10.1038/ni.3691.
   PubMed Web of Science ®Google Scholar
• Namour F, Diderichsen PM, Cox E, Vayssière B, Van der Aa A, Tasset C, Van‘t Klooster G. Pharmacokinetics and pharmacokinetic/pharmacodynamic modeling of filgotinib (GLPG0634), a selective JAK1 inhibitor, in support of phase IIB dose selection. Clin Pharmacokinet. 2015;54(8):859–874. doi:10.1007/s40262-015-0240-z.
   PubMed Web of Science ®Google Scholar
• Lee J, Lee J, Kwok SK, Baek S, Jang SG, Hong S-M, Min J-W, Choi SS, Lee J, Cho M-L, et al. JAK −1 inhibition suppresses interferon-induced BAFF production in human salivary gland. Arthritis Rheumatol. 2018;70(12):2057–2066. doi:10.1002/art.40589.
   PubMed Web of Science ®Google Scholar
• Chiriac MT, Buchen B, Wandersee A, Hundorfean G, Günther C, Bourjau Y, Doyle SE, Frey B, Ekici AB, Büttner C, et al. Activation of epithelial signal transducer and activator of transcription 1 by interleukin 28 controls mucosal healing in mice with colitis and is increased in mucosa of patients with inflammatory bowel disease. Gastroenterology. 2017;153(1):123–138 e8. doi:10.1053/j.gastro.2017.03.015.
   PubMed Web of Science ®Google Scholar
• Ostvik AE, Svendsen TD, Granlund AVB, Doseth B, Skovdahl HK, Bakke I, Thorsvik S, Afroz W, and Walaas GA, et al. Intestinal epithelial cells express immunomodulatory ISG15 during active ulcerative colitis and Crohn’s disease. J Crohns Colitis. 2020. doi:10.1093/ecco-jcc/jjaa022.
   Google Scholar
• Tang Y, Tan SA, Iqbal A, Li J, Glover SC. STAT3 genotypic variant rs744166 and increased tyrosine phosphorylation of STAT3 in IL-23 responsive innate lymphoid cells during pathogenesis of Crohn’s disease. J Immunol Res. 2019;2019:9406146. doi:10.1155/2019/9406146.
   PubMed Web of Science ®Google Scholar
• Daperno M, D’Haens G, Van Assche G, Baert F, Bulois P, Maunoury V, Sostegni R, Rocca R, and Pera A, et al. Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: The SES-CD. Gastrointest Endosc. 2004;60(4):505–512. doi:10.1016/s0016-5107(04)01878-4.
   PubMed Web of Science ®Google Scholar
• D’Haens GR, Geboes K, Peeters M, Baert F, Penninckx F, Rutgeerts P. Early lesions of recurrent Crohn’s disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology. 1998;114(2):262–267. doi:10.1016/s0016-5085(98)70476-7.
   PubMed Web of Science ®Google Scholar
• Reinisch W, De Hertogh G, D’Haens G, Li W, Serone A, Tasset C, Van der Aa A, Vermeire S. P633 concordance between endoscopy and histology scores at baseline and following induction therapy with the JAK1 inhibitor filgotinib in active Crohn’s disease: Results from FITZROY study. J Crohns Colitis. 2018;12(supplement_1):S430. doi:10.1093/ecco-jcc/jjx180.760.
   Google Scholar
• Ronneberger O, Fischer P, Brox T. U-Net: Convolutional networks for biomedical image segmentation. arXiv:150504597 [csCV]; 2015.
   Google Scholar
• Gomollon F, Dignass A, Annese V, Tilg H, Assche GV, Lindsay JO, Peyrin-Biroulet L, Cullen GJ, and Daperno M, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: Part 1: Diagnosis and medical management. J Crohns Colitis. 2017;11(1):3–25. doi:10.1093/ecco-jcc/jjw168.
   PubMed Web of Science ®Google Scholar
• Billiet T, Cleynen I, Ballet V, Ferrante M, Van Assche G, and Gils A, et al. Prognostic factors for long-term infliximab treatment in Crohn’s disease patients: A 20-year single centre experience. Aliment Pharmacol Ther. 2016;44(7):673–683. doi:10.1111/apt.13754.
   PubMed Web of Science ®Google Scholar
• Weiser M, Simon JM, Kochar B, Tovar A, Israel JW, Robinson A, Gipson GR, Schaner MS, Herfarth HH, Sartor RB, et al. Molecular classification of Crohn’s disease reveals two clinically relevant subtypes. Gut. 2018;67(1):36–42. doi:10.1136/gutjnl-2016-312518.
   PubMed Web of Science ®Google Scholar
• Nardone OM, Cannatelli R, Zardo D, Ghosh S, Iacucci M. Can advanced endoscopic techniques for assessment of mucosal inflammation and healing approximate histology in inflammatory bowel disease? Therap Adv Gastroenterol. 2019;12:1756284819863015. doi:10.1177/1756284819863015.
   Web of Science ®Google Scholar